Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00192556
Other study ID # FITTCET_1
Secondary ID WHO-TDR ID A3074
Status Completed
Phase N/A
First received September 11, 2005
Last updated February 8, 2007
Start date March 2005
Est. completion date August 2006

Study information

Verified date February 2007
Source Menzies School of Health Research
Contact n/a
Is FDA regulated No
Health authority Australia: National Health and Medical Research Council
Study type Interventional

Clinical Trial Summary

This study will examine whether food is a cost-effective method for improving treatment compliance for TB patients in Timor Leste. Our hypothesis is that the provision of locally available, locally acceptable, cheap and highly nutritious food at the clinic will encourage patients to come for daily directly observed treatment, and thus improve the chance of TB cure and decrease the chance of the development of TB drug resistance. Primary outcome will be successful completion of treatment and secondary outcomes will include treatment compliance and clinical and biological measures of nutritional improvement.


Description:

We propose to conduct a randomised controlled trial of a food intervention to improve compliance in East Timor. Patients will be diagnosed in the usual way and given the opportunity to enrol in the study. Consenting individuals will be randomised to receive the intervention (meal at the clinic daily during the first two months of treatment and a food parcel fortnightly during the other six months of treatment) or standard care (nutritional advice only). The primary outcome will be TB cure rates and the secondary outcomes will include response to treatment (weight gain, decreased symptoms, sputum clearance) and percentage of days attended at the clinic. In conjunction with this study of TB treatment compliance we will collect blood samples to measure micro-nutrient changes in response to the food intervention. A cost-effectiveness analysis of the intervention will also be performed.

We plan to do a pilot study in three urban clinics in Dili to establish feasibility and provide pilot data for other funding applications so that, if the intervention does improve compliance, and funding applications are successful, we can expand the project to include rural districts in conjunction with the National TB Control Program. Ultimately, the health outcome addressed by this project is improved control of tuberculosis in a high burden, low income setting. Better compliance with tuberculosis treatment at the community level will contribute to this process.

TRIAL OBJECTIVES AND PURPOSES

The specific objectives of the project are:

1. Design a locally appropriate food intervention to improve adherence to TB treatment and TB treatment outcomes in East Timor; and

2. Conduct a study of the intervention in three clinics in Dili. If this pilot study is successful, we will use our experience and pilot data to obtain funds to generalise the intervention to rural clinics as well.

3. Food incentives are an achievable, effective method of encouraging full adherence to DOTS and thus improved cure rates in East Timor;

4. Locally available, whole food supplements are a cost-effective intervention to improve cure rates in East Timor; and

5. Lessons learned in East Timor are adaptable to other settings in other parts of the world.

TRIAL DESIGN

Expected Outcomes and its measurements :

1. To show statistically significant differences in treatment success (cure rate) between the intervention and the control arm. We will assess the sputum clearance, treatment compliance and treatment completion rates and compare the two groups.

2. To show the effectiveness of food supplementation in improving compliance with treatment. In the intensive phase of treatment (usually the first two months), we will compare the observed versus expected daily visits to the clinic, compliance with daily medications and the default rate between the intervention and control arms. In the continuation phase of treatment (usually 6 months), we will compare the observed versus expected fortnightly visits to the clinic, daily medication diaries and default rates between the two groups.

3. To show a statistically significant difference in nutritional status between the intervention arm and the control arm. We will measure clinical improvement, sputum clearance (in sputum smear positive patients), gain in BMI, changes in bio-impedence and improvement in levels of micronutrients in both groups.

4. To demonstrate the cost-effectiveness of the intervention to improve TB control in East Timor.

Randomisation Patients will be randomly assigned to receive one of two interventions: food supplements or nutritional advice (standard care). The random assignment to intervention group will be provided by the statistician at the Menzies School of Health Research. The random allocation sequence will be computer-generated (Stata Version 8.0) and concealed from all investigators throughout the study. Allocation will be stratified by community health clinic and by the TB diagnosis (sputum smear positive and other). Block randomisation will be used to maintain similar numbers of participants in both intervention groups and to minimise the potential influence of time of enrolment. The random allocation will be in sealed envelopes in two boxes (smear positive and other) in each clinic. Prior to opening the envelope, the research assistant will complete the randomisation form to check if the patient is eligible for enrolment, obtain informed consent and complete the enrolment questionnaire. The research assistant will then inform the local investigator of the name of the patient, the time of randomisation and the randomisation number.

Outcome Assessment

1. The primary outcome measure will be the proportion of patients who successfully complete the eight month course of TB treatment and achieve cure in each group (treatment success) and the proportion of patients who do not complete treatment (defaulters) or have persistent disease (treatment failure). The primary analysis will be by intention to treat. All participants in the study will contribute an outcome for analysis.

2. Secondary analyses will be conducted to evaluate the proportion of clinic visits compared with expected and response to treatment measures: symptoms (cough, sputum, fever); changes in weight, BMI and bio-impedence; sputum clearance; and micronutrient measurements.

3. The primary outcome (treatment success) will be determined by an independent observer (based in Darwin) who will be blinded to the intervention received by the patients.


Recruitment information / eligibility

Status Completed
Enrollment 270
Est. completion date August 2006
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 15 Years and older
Eligibility Inclusion Criteria:

1. Adults 18 years of age or older;

2. Have sputum smear positive or sputum smear negative pulmonary or extrapulmonary TB, using the standard NTP definitions for these diagnoses;

3. Have never received more that one month of anti-tuberculosis treatment in the past (that is, only new cases of TB will be included).

4. Agree to continue treatment at the clinic of diagnosis for the full eight month course of treatment.

5. Not pregnant.

6. Agree to enrol in the study.

Exclusion Criteria:

1. Children less than 18 years of age,

2. TB patients who have previously received treatment for TB for more than one month,

3. Not willing to continue treatment at the clinic for the full course.

4. TB Patient who are currently pregnant,

5. TB patients who are not willing to enrol in the study.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Behavioral:
food


Locations

Country Name City State
Australia Menzies School of Health Research Darwin Northern Territory

Sponsors (3)

Lead Sponsor Collaborator
Menzies School of Health Research Universidade da Paz, World Health Organization

Country where clinical trial is conducted

Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary proportion of patients who successfully complete TB treatment and achieve cure.
Secondary proportion of clinic visits compared with expected
Secondary response to treatment measures: symptoms (cough, sputum, fever);
Secondary changes in weight;sputum clearance;
Secondary micronutrient measurements.
See also
  Status Clinical Trial Phase
Recruiting NCT05738681 - Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial Phase 2/Phase 3
Recruiting NCT05526885 - Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa N/A
Completed NCT04369326 - Community Initiated Preventive Therapy for TB N/A
Recruiting NCT04568967 - TB-CAPT EXULTANT - HIV N/A
Completed NCT02337270 - Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol Phase 1
Not yet recruiting NCT06253715 - Shortened Regimen for Drug-susceptible TB in Children Phase 3
Recruiting NCT04271397 - Immunological Biomarkers in Tuberculosis Management N/A
Withdrawn NCT03639038 - Tuberculosis Diagnosis by Flow Cytometry
Completed NCT03199313 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid Phase 1
Recruiting NCT04975178 - Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa Phase 3
Completed NCT04463680 - Rifampin and the Contraceptive Implant Phase 4
Completed NCT03973970 - Assessing the Ability of the T-SPOT®.TB Test (IQ)
Recruiting NCT04230395 - Alcohol Reduction Among People With TB and HIV in India N/A
Completed NCT04874948 - Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment Phase 1
Active, not recruiting NCT02906007 - Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV Phase 1/Phase 2
Not yet recruiting NCT05917210 - Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda N/A
Not yet recruiting NCT05845112 - Start Taking Action For TB Diagnosis
Not yet recruiting NCT06017843 - Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding N/A
Active, not recruiting NCT02715271 - Study of TB Lesions Obtained in Therapeutical Surgery
Completed NCT02781909 - Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis Phase 2